Mildly to Moderately Active Extensive Ulcerative Colitis When Budesonide MMX Plus 5-ASA Has Not Achieved Remission
Clinical Scenario
This protocol applies to adults with mildly to moderately active extensive ulcerative colitis who remain symptomatic after a prior induction attempt with oral 5-ASA–based therapy.
Previous Treatment — Failure Condition
The preceding regimen used oral budesonide MMX in addition to oral 5-ASA to induce remission. Escalation to this protocol is appropriate when that combination has not reached the required induction targets:
- Absence of rectal bleeding
- Mayo endoscopic score of 0 or 1
Next-Line Approach
In extensive colitis that fails to respond to 5-ASA–based therapy, guidelines recommend escalating to a course of oral systemic corticosteroids to induce remission.
The full regimen — including agent selection, dosing strategy, and monitoring — is available in the structured protocol below.
Expected response indicators (within the first week of treatment):
- Decreasing rectal bleeding
- Decreasing stool frequency
References
DOI: 10.14309/ajg.0000000000003463
- In patients with mildly to moderately active extensive colitis, oral 5-ASA at a dose of at least 2.0 g daily is recommended to induce remission
- In patients with UC of any extent who fail to respond to 5-ASA therapy, we recommend oral systemic corticosteroids to induce remission
- The typical starting doses of oral prednisone are 40–60 mg daily, usually in a single dose, and clinical response is expected within 5–7 days of treatment.
View source ↗